COMP <GO>
JBI vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
Janus International Group Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: JBI 3
— TMO 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: TMO
LAST: $4.56 (+7.29%) • MKT CAP: $622.1M
roic
7.90%
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JBI VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JBI | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 38.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 7.90% | 9.30% | -1.40 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 8.7x | 30.4x | -21.70 | JBI | /valuation <GO> |
| Free Cash Flow Yield | 18.32% | 2.40% | +15.92 | JBI | /fcf-yield <GO> |
| Operating Margin | 12.60% | 17.40% | -4.80 | TMO | /operating-margins <GO> |
| Net Profit Margin | 6.10% | 15.10% | -9.00 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -8.30% | 3.90% | -12.20 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.13 | 4.50 | -2.37 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.1 | 62.9 | -2.78 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.8x | 36.3x | -25.50 | JBI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $622.1M | $262.22B | -$261.60B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JBI REV | TMO REV | JBI GROSS % | TMO GROSS % | JBI FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $884.2M | $44.56B | 38.8% | — | $114.0M | $6.29B |
| FY 2024 | $963.8M | $42.88B | 41.3% | — | $133.9M | $7.27B |
| FY 2023 | $1.07B | $42.86B | — | — | $215.0M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JBI // BETA —
TMO // BETA 0.94